

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



748

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>6</sup>:</b> <b>A61K 9/24, 9/36, B32B 23/00</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/44591</b>
			<b>(43) International Publication Date:</b> 10 September 1999 (10.09.99)
<b>(21) International Application Number:</b> PCT/US99/04192 <b>(22) International Filing Date:</b> 26 February 1999 (26.02.99) <b>(30) Priority Data:</b> 60/077,133 6 March 1998 (06.03.98) US <b>(71) Applicant:</b> ALZA CORPORATION [US/US]; 950 Page Mill Road, P.O. Box 10950, Palo Alto, CA 94303-0802 (US). <b>(72) Inventors:</b> EDGREN, David, E.; 261 Francisco Street, El Granada, CA 94018 (US). LI, Shu; 36943 Papaya Street, Newark, CA 94560 (US). BHATTI, Gurdish, K.; 246744 Rancho Higuera Road, Fremont, CA 94539-6946 (US). WONG, Patrick, S., L.; 1533 Burlingame Avenue, Burlingame, CA 94010 (US). SKLUZACEK, Robert, R.; 6053 Bennington Drive, Newark, CA 94560 (US). <b>(74) Agents:</b> SABATINE, Paul et al.; Alza Corporation, 950 Page Mill Road, P.O. Box 10950, Palo Alto, CA 94303-0802 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> EXTENDED RELEASE DOSAGE FORM			
<b>(57) Abstract</b>  A dosage form comprising a composition comprising a drug surrounded by an interior and an exterior wall with an exit for administering the drug to a patient; and a method of using the dosage form are disclosed for an indicated therapy.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Lichtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**EXTENDED RELEASE****DOSAGE FORM****CROSS-REFERENCE TO RELATED APPLICATION**

5

This application claims the benefits of provisional application U.S. Serial No. 60,077,133, filed March 6, 1998 under 35 U.S.C. §119(e).

**FIELD OF THE INVENTION**

10

This invention pertains to both a novel and therapeutically useful dosage form. The invention, more particularly, relates to a dosage form that administers a dose of drug in an extended and linear-release profile for an indicated therapy. Specifically, the invention concerns a dosage form comprising a drug formulation enveloped by two walls with the formulation and walls acting in concert to provide the extended, linear-nondeclining-release drug delivery profile. The invention concerns also a method of administering the dosage form to provide a dose of drug for therapy.

15

20

**BACKGROUND OF THE INVENTION**

To improve the effectiveness of drug therapy and to reduce possible systematic side effects, many attempts have been made to deliver drugs in a controlled profile to human patients. The advantage of controlled release dosage forms are well-known in both the pharmaceutical and medical sciences. The therapeutical benefits of controlled-release dosage forms include the pharmacokinetic ability to maintain a preplanned blood level of an administered drug over a comparatively longer period of time. The therapeutical benefits include also a simultaneous increase in patient compliance and a reduction in the number of doses of drug administered to a patient.

25

30

5 The prior art made available controlled release dosage that sought to provide a drug release rate profile that matched the blood physiological and chrono-pharmacological requirements needed for therapy. For example, an osmotic dosage form for delivering various drugs to a patient environment of use is presented in U.S. Patent No. 3,845,770 issued to patentees Theeuwes and Higuchi, and in U.S. Patent No. 3,916,899 issued to the same patentees. The dosage forms disclosed in these patents are manufactured comprising a wall that surrounds a compartment comprising a drug with an exit in the wall for delivering the drug to a patient. In U.S. Patent Nos. 4,008,719; 4,014,334; 10 4,058,122; 4,116,241; and 4,160,452 patentees Theeuwes and Ayer made available dosage forms comprising an inside and an outside wall made of poly(cellulose acylate) for delivering a dosage of drug to a patient in need thereof.

15 The history of the prior art dosage forms indicates a serious need exists for a novel and useful dosage form that provides an unexpected advancement in the science of dosage forms. For example, the prior art dosage forms lack the present ability to mask an unpleasant taste, they did not maintain the stability of a drug formulation, and the dosage forms did not protect a drug from oxidation. Then too, the drug formulation in the dosage 20 form permitted the drug release profile to decline over time, thereby administering a nontherapeutic dose of drug. The wall of the dosage forms exposed to the gastrointestinal tract were lipophilic, they absorbed endogenous fats and consequently evidenced a decrease in structural integrity as seen in flaws or cracks in the wall. Moreover, the dosage forms 25 wall and its drug formulation did not act in concert for providing a controlled linear drug delivery profile over an extended time. Likewise, prior art dosage forms were formulated with water-leachable components within the membrane to control delivery rate of drug which water-leachable components diffused from the membrane against the direction of osmotic water flux making reproducibility and control of delivery rate patterns difficult, as seen in 30 U.S. Patent No. 5,160,744.

It is clear from the above presentation that a long-felt need exists for a dosage form comprising a walled structure and a drug formulation that function together for administering orally a drug at a controlled and sustained-release drug delivery profile with time. The need exists for a dosage form for administering a drug in a linear profile for treating infectious diseases, respiratory diseases, the cardiovascular system, blood and spleen, the digestive system, metabolic disorders, the endocrine system, the urogenital tract, sexually transmitted diseases, the nervous system, the locomotor system, psychiatric disorders and for providing symptomatic care. A dosage form is needed for replacing immediate-release dose-dumping forms administered three or four times daily. There are serious reasons for seeking a dosage form that replaces immediate-release forms, including a means for reducing peak-blood levels followed by a sharp drop in blood levels, a means for lessening side effects, a means for manufacturing the structural integrity of the dosage form, and a means for reducing the number of solvents used to manufacture the dosage form.

### **OBJECTS OF THE INVENTION**

Accordingly, in view of the above presentation, it is an immediate object of this invention to provide both a novel and a useful dosage form that overcomes the disadvantages associated with the prior art.

Another object of the present invention is to satisfy a long-felt need by making available a dosage form that administers a drug in a linear profile over time.

Another object of the present invention is to provide a dosage form comprising a formulation comprising a drug and a first and second wall which formulation and walls operate together to deliver a drug in a linear rate over an extended time.

Another object of the invention is to provide a dosage form comprising an inside wall and an outside wall which outside wall protect the inside wall from the environment of the gastro-intestinal tract.

Another object of the invention is to provide a bilayer wall that maintains its physical and chemical integrity during the administration of a drug.

Another object of the present invention is to provide a dosage form manufactured as an osmotic drug delivery device by standard manufacturing procedures into sizes, shapes and structures that represent an advancement in the drug delivery art.

Another object of the invention is to make available a dosage form comprising an outside bioprotective wall that shields the dosage form from injury and/or destruction in a gastrointestinal environment.

Another object of the invention is to provide a dosage form comprising ethylcellulose and a hydroxyalkylcellulose wall formed from a single solvent system.

Another object of the invention is to provide a dosage form comprising an interior wall comprising an ethylcellulose and a hydroxypropylalkylcellulose shielded by an exterior wall comprising a poly(cellulose acylate) and other wall-forming ingredients.

Another object of this invention is to provide a dosage form comprising an inside wall that comprises a hydrophobic polymer insoluble in the digestive system and hydrophilic polymer soluble in the digestive system which latter polymer dissolves from the wall thereby increasing the porosity and increasing the fluid flux of the wall.

Another object of the invention is to provide a transport mechanism whereby water-soluble flux enhancers within the interior wall during the operation of the dosage form are transported by diffusion from the wall in the same direction as the osmotic water-flow passing through the bilayer wall.

Another object of the invention is to provide a dosage form comprising an interior seamless wall that surrounds a formulation containing a drug, and an exterior seamless wall that surrounds the interior wall, which dual walls avoid a break-up in the gastrointestinal tract while keeping the structural integrity of the dosage form.

Another object of the invention is to provide a method for treating a patient with a medication administered from a controlled-release dosage form.

Another object of this invention is to provide a method for administering an effective dose of a medicament at a sustained release rate to provide a therapeutically effective blood level of the medicament for 30 minutes to 24 hours, which sustained release rate provided by the invention is free from changes induced by the environment of the gastrointestinal tract.

Another object of the invention is to provide a method for administering an opioid medicament from a sustained release dosage form into the gastrointestinal tract for producing an opioid medicament level in the blood of a patient for an extended time of 30 minutes to 24 hours, that is longer than the 0 to 4 hours provided by a conventional nonextended rapid-release dosage form.

Other objects, features, aspects, and advantages of the invention will be more apparent to those versed in the drug dispensing art from the following detailed specification taken in conjunction with the drawing figures and the accompanying claims.

### **BRIEF DESCRIPTION OF DRAWINGS**

In the drawing figures, which are not drawn to scale, but are set-forth to illustrate various manufactures of the invention, the drawing figures are as follows:

Drawing Figure 1, is a general view of a dosage form provided by this invention, that is designed, shaped and adapted for the oral administration of a drug at a controlled rate over an extended time to a human patient in need of drug therapy.

Drawing Figure 2, is a general view of the dosage form of drawing Figure 1, in opened section, depicting a dosage form provided by this invention comprising an internally housed pharmaceutically-acceptable drug composition surrounded by an interior and exterior wall.

Drawing Figure 3, is an opened view of drawing Figure 1, illustrating a dosage form comprising a drug composition, and a separate but initially contacting push-displacement composition comprising means for pushing the drug composition from the dosage form with both compositions surrounded by an interior wall and an exterior wall.

Drawing Figure 4, is an opened view of the dosage form of drawing Figure 1, depicting the dosage form in operation as a fluid sensitive pore former begins to dissolve, and is eluted from the interior wall to increase the porosity of the interior wall, while simultaneously keeping the physical and chemical integrity of the exterior wall.

Drawing Figure 5, represents a plot of the dissolution of pore former candidates of the interior wall as a function of osmotic pressure.

Drawing Figures 6, 7, and 8 illustrate release patterns and comparison release patterns for dosage forms with different coating compositions.

In the drawing figures, and in the specification, like parts and like ingredients, are identified by like numbers. The terms that appear earlier in the specification, and in the description of the drawing figures, as well as in embodiments thereof, are further described in the specification.

#### **DETAILED DESCRIPTION OF DRAWINGS**

Turning attention now to the drawing figures in detail, which drawing figures are examples of a dosage form and a drug composition provided by this invention, and which examples are not to be construed as limiting the invention, one example of a dosage form is seen in drawing Figure 1. In drawing Figure 1, a dosage form 10 is seen comprising a body member 11 that comprises an exterior wall 12. The exterior wall 12 surrounds an interior wall and an internal compartment, not seen in drawing Figure 1. Dosage form 10 comprises at least one exit 13 that connect the exterior environment, such as the gastrointestinal tract of a human patient, with the interior of the dosage form.



Dosage form 10, of drawing Figure 2, illustrates a dosage form that possesses controlled-release delivery kinetics. The dosage form delivers a drug, or a drug and its pharmaceutically-acceptable salt to a patient in need of drug therapy. The phrase, controlled-release denotes the dosage form provides a linear drug release with time, or a zero order delivery rate of drug. Dosage form 10 controls or governs the delivery of drug 14, represented by dots 14, from an internal space or compartment 15. Dosage form 10 delivers drug 14 at a measured rate per unit time over an extended or sustained-release time of six hours to twenty-four hours.

The dosage forms provided by this invention, are useful for establishing therapeutic drug levels in the blood, including the plasma, for therapy. Dosage form 10, as seen in the accompanying figures, embraces the shape of a dosage tablet, and it can embrace the shape of a caplet, or a buccal, or a sublingual dosage form. The sustained-release dosage form of this invention provides extended-continuous delivery greater than conventional, noncontrolled tablets, or noncontrolled-nonsustained release tablets and/or capsules that exhibit a dose-dumping of their drug.

Dosage form 10 of drawing Figure 2, comprises exterior wall 12 that surrounds compartment 15. Exterior wall 12 comprises totally, or in at least a part a semi-permeable composition. The semipermeable composition is permeable to the passage of an aqueous or an aqueous-biological fluid present in the gastrointestinal tract, and wall 12 is impermeable to the passage of drug 14. Wall 12 is nontoxic, and it maintains its physical and chemical integrity during the dispensing time of drug 14. The phrase, maintains its physical and chemical integrity means wall 12 does not lose its structure, and it does not undergo a chemical change during the dispensing of drug 14.

Wall 12 comprises a composition that does not adversely affect an animal, a human, or components of the dosage form. Compositions for forming wall 12 are, in one embodiment, comprised of a member selected from the group consisting a cellulose ester polymer, a cellulose ether polymer

and a cellulose ester-ether polymer. These cellulosic polymers have a degree of substitution, DS, on the anhydroglucose unit, from greater than 0 up to 3 inclusive. By "degree of substitution" is meant the average number of hydroxyl groups originally present on the anhydroglucose unit comprising the cellulose polymer that are replaced by a substituting group. Representative wall 12 polymers comprise a member selected from the group consisting of cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, mono-, di- and tricellulose alkanylates, mono-, and di- and tricellulose alkinylates. Exemplary polymers include cellulose acetate having a DS of up to 1 and an acetyl content of up to 31 weight %; cellulose acetate having a DS of 1 to 2 and any acetyl content of 21 to 35%; cellulose acetate having a DS of 2 to 3 and an acetyl content of 35 to 44.8%; and the like. More specific cellulosic polymers comprise cellulose propionate having a DS of 1.8, a propyl content of 39.2 to 45% and a hydroxyl content of 2.8 to 5.4%; cellulose acetate butyrate having a DS of 1.8, an acetyl content of 13 to 15% and a butyl content of 17% to 53% and a hydroxyl content of 0.5 to 4.7%; cellulose triacylates having a DS of 2.9 to 3, such as cellulose trivalerate, cellulose trilaurate, cellulose tripalmitate, cellulose trisuccinate and cellulose trioctanoate; celluloses diacylate having a DS of 2.2 to 2.6, such as cellulose disuccinate, cellulose dipalmitate, cellulose dioctanoate, cellulose dipentanoate, co-esters of cellulose, such as cellulose acetate butyrate, and cellulose acetate propionate, and blends of the above.

Additional semipermeable polymers comprise acetaldehyde dimethylcellulose acetate; cellulose acetate ethylcarbamate; cellulose acetate methylcarbamate; cellulose diacetate propylcarbamate; cellulose acetate diethylaminoacetate; ethyl acrylate methyl methacrylate, semipermeable polyamide; semipermeable polyurethane; semipermeable sulfonated polystyrene; semipermeable crosslinked selective polymer formed by the coprecipitation of a polyanion and polycation, as disclosed in U.S. Patent Nos. 3,173,876; 3,276,586; 3,541,005; 3,541,006 and 3,546,876; semipermeable polymers as disclosed by Loeb and Sourirajan in U.S. Patent No. 3,133,132;

semipermeable, lightly crosslinked polystyrenes; semipermeable crosslinked poly (sodium styrene sulfonate); semipermeable cross-linked poly (vinylbenzyltrimethyl ammonium chloride); and semipermeable polymers possessing a fluid permeability in the range of  $2.5 \times 10^{-8}$  to  $5 \times 10^{-2}$  (cm<sup>2</sup>/hr•atm), expressed per atmosphere of hydrostatic or osmotic pressure difference across the semipermeable exterior wall 12. The polymers are known to the polymer art in U.S. Patents Nos. 3,845,770; 3,916,899 and 4,160,020; and in Handbook of Common Polymers, by Scott, J.R. and Roff, W.J. 1971, CRC Press, Cleveland, OH. Wall 12, in a present manufacture can be coated from a substantially single solvent system, such as acetone if coated from a solution, or water if coated as a dispersion.

Dosage form 10 comprises an interior wall 16. The interior wall 16 faces compartment 15, and exterior wall 12. Exterior wall 12 comprises a surface that faces the environment of use. Interior wall 16 comprises ethylcellulose, one hundred weight percent, (100 wt%), or in another manufacture a composition comprising a blend of 40 to 99 wt% ethylcellulose and 1 to 60 wt% hydroxyalkylcellulose with the total weight of the compositional blend equal to 100% wt. The ethylcellulose used for the interior wall is nontoxic, insoluble in water, and insoluble in gastrointestinal fluid. The interior ethylcellulose wall is coated from a single anhydrous solution, or the interior ethylcellulose wall is coated from a dispersion comprising the single solvent water. The ethylcellulose used for the purpose of this invention comprises a 15 to 60 weight percent ethoxy content, a viscosity of 4 to 200 centipoises, or higher, and a 5,000 to 1,250,000 weight average molecular weight. The hydroxyalkyl-cellulose comprises an alkyl of 1 to 5 carbons as represented by hydroxypropylcellulose. The hydroxypropylcellulose is homogeneously blended with the ethylcellulose, and is identified by a wavy line 17 in interior wall 16. The hydroxypropylcellulose 17 in interior wall 16 comprises a 7,500 to 1,500,000 weight-average molecular weight, and it is soluble in water below 40°C and in ethyl alcohol and displays a solubility in water which sensitive to osmotic pressure or ionic strength.

Interior wall 16 comprising hydroxypropylcellulose provides unexpected properties for this invention. For instance, ethylcellulose is hydrophobic and accordingly its fluid permeability is low which hinder sufficient water flux passing through wall 16 to provide a wide-range of delivery rates. This invention, enhances the fluid permeability of wall 16 by blending a hydrophilic fluid flux enhancer, which operates as a pore former in the first ethylcellulose wall. The hydrophilic enhancer increases the permeability of the ethylcellulose wall as it is dissolved and/or leached therefrom, to provide fluid-control pores. However, if the dosage form is manufactured with a single wall comprising a composition of ethylcellulose and hydroxypropylcellulose, as the pores are formed, the pores allow lipids which are present in the gastrointestinal tract to sorb into this unprotected wall, which leads to an unaccepted change in this nonprotected single wall. That is, the hydrophobic lipids cause the unprotected wall to become soft, flaccid and tearable as the lipid functions as a plasticizer within the ethylcellulose. The presence of the sorbed lipids cause the porous wall to become hydrophobic again, thereby reversing the desirable effects of the hydrophilic flux enhancer. The present invention unexpectedly discovered by providing an outside wall comprising a cellulose acylate, the outside wall excludes and prevents the lipids of the gastrointestinal tract from contacting and reaching the interior wall. The interior ethylcellulose-hydroxypropylcellulose-exterior cellulose acylate bilayer wall provides a wide range of low to high fluxes. An additional advantage provided by the present invention is each wall can be coated from a single solvent to provide reproducible interior and exterior walls with reproducible permeability and mechanical properties.

In drawing Figure 2, internal compartment 15 comprises a single homogenous composition. The compartment 15 comprises therapeutic agent 14, represented by dots. The term therapeutic agent as used herein included medicines or drugs, nutrients, vitamins, food supplements, and other beneficial agents that provide a therapeutic or a benefit to animals, including a warm-blooded animal, humans, farm animals, and zoo animals. Representative of drugs 14 comprises an opioid analgesic selected from the

group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, diepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazone, ethoheptazine, ethylmethylthiambutene, ethylmorphine, propylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroenitabas, hydrocypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphine, phenazocine, phenoperidine, piminodine, pirtramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, and tilidine. The dose of opioid drug 14 is 0.1 µg to 700 mg.

The opioid analgesic 14 can be present in compartment 15 alone, or the opioid analgesic 14 can be present with a nonopioid analgesic 14.

Examples of nonopioid analgesic comprise a member selected from the group consisting of acetaminophen, aminobenzoate potassium, aminobenzoate sodium, aspirin, benoxaprofen, benzydamine, bicifadine, decibuprofen, fenoprofen, flurbiprofen, ibufenac, indoprofen, ibuprofen, ketoprofen, naproxen, naproxol, salicylamide, sodium salicylate, and salicylate potassium. The dose of nonopioid analgesic 14 is 0.5 mg to 600 mg. An analgesic composition in compartment 15 comprises 1.0 mg to 750 mg of both the opioid analgesic and nonopioid analgesic.

The analgesic drug comprising the opioid analgesic and the nonopioid analgesic can be present as the free base, free acid, or as a therapeutically acceptable derivative, or as a therapeutically acceptable salt. The therapeutically acceptable salts comprise inorganic salts, organic salts, including hydrobromide, hydrochloride, mucate, N-oxide, sulfate, acetate, phosphate dibasic, phosphate monobasic, acetate trihydrate,

bi(heptafluorobutyrate), bi(methylcarbamate), bi(pentafluoropropionate),  
bi(pyridine-3-carboxylate), bi(trifluoroacetate), bitartrate, chlorhydrate, and  
sulfate pentahydrate, benzenesulfonate, benzoate, bicarbonate, bitartrate,  
bromide, calcium edetate, camsylate, carbonate, chloride, citrate,  
5 dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate,  
gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine,  
hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate,  
lactobionate, malate, maleate, mandelate, mesylate, methylbromide,  
methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate (embonate),  
10 pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate,  
subacetate, succinate, sulfate, tannate, tartrate, teoclate, triethiodide,  
benzathine, chlorprocaine, choline, diethanolamine, ethylenediamine,  
meglumine, and procaine, aluminum, calcium, lithium, magnesium,  
potassium, sodium propionate, zinc, and the like.

15 Dosage form 10, in compartment 15 comprises a pharmaceutically  
acceptable polymer hydrogel 18, as represented by horizontal dashes.  
Representative polymer hydrogels comprise a maltodextrin polymer  
comprising the formula  $(C_6H_{12}O_5)_\lambda \cdot H_2O$ , wherein  $\lambda$  is 3 to 7,500, and the  
maltodextrin polymer comprises a 500 to 1,250,000 number-average  
20 molecular weight; a poly(alkylene oxide) represented by poly(ethylene oxide)  
and poly(propylene oxide) having a 50,000 to 750,000 weight-average  
molecular weight, and more specifically represented by a poly(ethylene oxide)  
of at least one of 100,000, 200,000, 300,000, or 400,000 weight-average  
molecular weights; an alkali carboxyalkylcellulose, wherein the alkali is  
25 sodium, lithium, potassium or calcium, and alkyl is 1 to 5 carbons such as  
methyl, ethyl, propyl or butyl of 10,000 to 175,000 weight-average molecular  
weight; and a copolymer of ethylene-acrylic acid, including methacrylic and  
ethacrylic acid of 10,000 to 1,500,000 number-average molecular weight.  
The therapeutic composition comprises 5 to 400 mg of a polymer hydrogel.  
30 The therapeutic composition can be manufactured into dosage form 10 and it  
can be used as the therapeutic composition for its therapeutic effect. The  
hydrogel polymer exhibits an osmotic pressure gradient across bilayer interior

5 wall and exterior wall thereby imbibing fluid into compartment 15 to form a solution or a suspension comprising drug 14 that is hydrodynamically and osmotically delivered through a passageway from dosage form 10.

10 Dosage form 10 comprises a binder 19 represented by vertical dashes 19. The binder imparts cohesive qualities to the composition. Representative materials useful for this invention as binders comprise a member selected from the group consisting of starch, gelatin, molasses, a vinyl polymer comprises 5,000 to 350,000 viscosity-average molecular weight, represented by a member selected from the group consisting of poly-n-vinylamide, poly-n-vinylacetamide, poly(vinyl pyrrolidone), also known as poly-n-vinylpyrrolidone, poly-n-vinylcaprolactone, poly-n-vinyl-5-methyl-2-pyrrolidone, and poly-n-vinylpyrrolidone copolymers with a member selected from the group consisting of vinyl acetate, vinyl alcohol, vinyl chloride, vinyl fluoride, vinyl butyrate, vinyl laurate, and vinyl stearate, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and mixtures of binders. The binders can be used as a solution, or in a dry form to prepare the therapeutic composition. The therapeutic composition comprises 0 to 100 mg of a binder and in a present manufacture from 0.01 to 50 mg of the binder.

20 Dosage form 10 comprises a lubricant 20 represented by the letter v. The lubricant is used during manufacture of the composition to prevent sticking to die walls or punch faces, generally to lessen adhesion. The lubricants are selected from the group consisting of polyethylene glycol, sodium stearate, oleic acid, potassium oleate, caprylic acid, sodium stearyl fumarate, magnesium palmitate, calcium stearate, zinc stearate, magnesium stearate, magnesium oleate, calcium palmitate, sodium suberate, potassium laurate, stearic acid, salts of fatty acids, salts of alicyclic acids, salts of aromatic acids, oleic acid, palmitic acid, a mixture of a salt of a fatty, alicyclic or aromatic acid, and a mixture of magnesium stearate and stearic acid. The amount of lubricant in the therapeutic composition is 0.01 to 20 mg.

30 Drawing Figure 3 depicts dosage form 10 in opened section illustrating internal compartment 15. Internal compartment comprises the therapeutic

composition containing drug 14, as described in detail in drawing Figure 2. The therapeutic composition of drawing Figure 2 is identified further in drawing Figure 3 as drug layer 21. Drug layer 21 comprises the ingredients described in drawing Figure 2 and the details previously disclosed are included in this description of drawing Figure 3. Drug layer 21 in drawing Figure 3 initially is in contact with push layer 22.

In drawing Figure 3, push layer 22 comprises 10 mg to 400 mg of an expandable osmopolymer 23 represented by squares. The osmopolymer 23 in layer 22 possesses a higher molecular weight than the hydrogel polymer 18 in the drug composition. The osmopolymer 23 comprises a member selected from the group consisting of a polyalkylene oxide and, a carboxyalkylcellulose and acrylates. The polyalkylene oxide possesses a 1,000,000 to 10,000,000 weight-average molecular weight. Representative of polyalkylene oxide include a member selected from the group consisting of polymethylene oxide, polyethylene oxide, polypropylene oxide, polyethylene oxide having a 1,000,000 molecular weight, polyethylene oxide possessing a 2,000,000 molecular weight, polyethylene oxide comprising a 3,000,000 to 8,000,000 molecular weight, polyethylene oxide comprising a 7,000,000, and 7,800,000 molecular weight, and cross-linked polymethylene oxide possessing a 1,000,000 molecular weight, and polypropylene oxide of 1,200,000 molecular weight. Typical osmopolymer 23 carboxyalkylcellulose in the expandable layer 22 comprises a 200,000 to 7,250,000 weight-average molecular weight. Representative carboxyalkylcellulose comprises a member selected from the group consisting of alkali carboxyalkylcellulose, sodium carboxymethylcellulose, lithium carboxyethylcellulose, calcium carboxymethylcellulose, potassium carboxy-methylcellulose, sodium carboxyethylcellulose, lithium carboxyalkylhydroxy-alkylcellulose, sodium carboxyethylcellulose, carboxyalkylhydroxyalkylcellulose, carboxymethylhydroxyethylcellulose, carboxethylhydroxyethylcellulose and carboxymethylhydroxypropylcellulose. Typical osmopolymer 23 acrylates comprise non-crosslinked polyacrylic acid, and polyacrylic acids crosslinked with allyl sucrose, allylpentacrythritol, or divinyl glycol, sodium or potassium



polyacrylic acid, and the like. The osmopolymers used for the push-expandable layer exhibit an osmotic pressure gradient across semipermeable wall 12. The osmopolymers imbibe fluid into dosage form 10, thereby swelling, expanding as a hydrogel or osmogel, whereby, they push the drug from the osmotic dosage form.

Push layer 22 comprises 0 to 200 mg, and presently 0.5 to 75 mg of an osmotically effective compound 24, represented by circles. The osmotically effective compounds are known also as osmagents and as osmotically effective solutes. They imbibe an environmental fluid, for example, from the gastrointestinal tract, into dosage form 10 for contributing to the delivery kinetics of push layer 22 and to the permeability characteristics of the interior wall 16. Representative of osmotically active compounds comprise a member selected from the group consisting of osmotic salts, such as sodium chloride, potassium chloride, magnesium sulfate, lithium phosphate, lithium chloride, sodium phosphate, potassium sulfate, sodium sulfate, potassium phosphate, osmotic carbohydrates; glucose, fructose, maltose and sorbitol; urea; osmotic acids; tartaric acid; citric acid; potassium acid phosphate; and a mixture of sodium chloride and urea.

Push layer 22 comprises 0 to 75 mg of a suspending agent used for providing stability and homogeneity to push layer 22. Suspending agent 25, represented by clear triangles comprises a hydroxypropylalkylcellulose that comprises an alkyl of 1 to 7 carbons, straight or branched, with the hydroxypropylalkylcellulose possessing a 9,000 to 450,000 number-average molecular weight. The hydroxypropylalkyl-cellulose is represented by a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylisopropyl-cellulose, hydroxypropylbutylcellulose and hydroxypropylpentylcellulose. Push layer 22 optionally comprises a hydroxyalkylcellulose, also represented by triangles 25. The hydroxyalkylcellulose is a viscosity-increasing suspending agent comprises a member selected from the group consisting of hydroxymethylcellulose, hydroxy-ethylcellulose, hydroxypropylcellulose and hydroxybutylcellulose comprising a 7,500 to 1,000,000 viscosity-average

molecular weight. The suspending agent include also polyvinylpyrrolidone, acacia, agar, locust bean gum, alginic acid, gum karaya, gum tragacaro, carrageenan, gum ghatti, guar gum, xanthan gum, and bentonite.

Push layer 22 comprises 0 to 5 mg of a nontoxic colorant, or dye 26 identified by a half-circle. The colorant 26 makes the dosage form more esthetic in appearance, and it serves to identify the dosage form during manufacture and during therapy. The colorants include Food and Drug Administrations Colorant (FD&C), such as FD&C No. 1 blue dye, FD&C No. 4 red dye, FD&C yellow No. 5, FD&C yellow No. 6, FD&C blue No. 2, FD&C green No. 3, FD&C cranberry red No. 40, red ferric oxide, yellow ferric oxide, black ferric oxide, titanium dioxide, carbon black, Opadry® comprising polycellulose, or starch, or cured polymers with dyes commercially available from Colorcon Corporation, West Point, Pennsylvania; erythrosine, allura red, sunset yellow and chlorophylls.

A lubricant 27, identified by hexagon is formulated into push-expandable layer 22. Typical lubricants comprise a member selected from the group consisting of polyethylene glycol, sodium stearate, potassium stearate, magnesium stearate, stearic acid, calcium stearate, sodium oleate, calcium palmitate, sodium laurate, sodium ricinoleate, potassium linoleate, glyceryl monstearate, glyceryl palmitostearate, halogenated castor oil, sodium lauryl sulfate, sodium stearyl fumarate, and zinc stearate. The amount of antiadherent lubricant in layer 22 is 0.01 to 10 mg.

An antioxidant 28, represented by right slanted dashes, is present in push-expandable formulation 22 to inhibit the oxidation of ingredients comprising expandable formulation 22. Expandable formulation 22 comprises 0.00 to 5 mg of an antioxidant. Representative antioxidants comprise a member selected from the group consisting of ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, a mixture of 2 and 3 tertiary-butyl-4-hydroxyanisole, butylated hydroxytoluene, sodium isoascorbate, dihydroguaretic acid, potassium sorbate, sodium ascorbate, sodium bisulfate, sodium metabisulfate, sorbic acid, potassium ascorbate, vitamin E, 4-chloro-2,6-ditertiary butylphenol, alphotocopherol, and propylgallate. The

antioxidant slow, or prevent the oxidization of the dosage form and its ingredients by atmospheric oxygen.

Dosage form 10, comprises another manufacture provided by the invention. Dosage form 10 comprises an overcoat not shown on the outer surface of wall 12 of dosage form 10. The overcoat is a therapeutic composition comprising 0.5 to 200 mg of drug and 0.5 to 275 mg of a pharmaceutically acceptable carrier selected from the group consisting of alkylcellulose, hydroxyalkylcellulose and hydroxypropylalkyl-cellulose. The overcoat is represented by methylcellulose, hydroxyethylcellulose, hydroxybutylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylethylcellulose and hydroxypropylbutylcellulose. The overcoat, carried by the outer surface of the exterior wall 12 distant from the compartment 15 and it can be formulated with 0 to 50 wt% of a plasticizer, opacifier, colorant, or antitack agent, not seen in drawing Figure 4. The overcoat provides therapy immediately as the overcoat dissolves or undergoes dissolution in the presence of gastrointestinal fluid and concurrently therewith delivers the drug into the gastrointestinal tract for immediate drug therapy.

Dosage form 10, manufactured as an osmotically controlled-release dosage form, comprises at least one passageway 13. The phrase "controlled-release" as used herein indicates that control is exercised over both the duration and the profile of the drug release pattern. The expression "passageway" as used for the purpose of this invention, includes aperture, orifice, bore, pore, porous element through which drug 14 can be pumped, diffuse or migrate through a fiber, capillary tube, porous overlay, porous insert, microporous member, and porous composition. The passageway 13 includes also a compound that erodes or is leached from wall 12 in the fluid environment of use to produce at least one passageway. Representative compounds for forming a passageway include erodible poly(glycolic) acid, or poly(lactic) acid in the wall; a gelatinous filament; a water-removable poly(vinyl alcohol); leachable compounds such as fluid-removable pore-forming polysaccharides, acids, salts, or oxides. A passageway can be

formed by leaching a compound from wall 12, such as sorbitol, sucrose, lactose, maltose or fructose, to form a controlled-release dimensional pore-passageway. The passageway can have any shape, such as round, triangular, square and elliptical, for assisting in the controlled-metered release of drug 14 from the dosage form. The dosage form can be manufactured with one or more passageways for example two passageways, in spaced-apart relation on one or more surfaces of the dosage form. A passageway and equipment for forming a passageway are disclosed in U.S. Patent Nos. 3,845,770 and 3,916,899 by Theeuwes and Higuchi; in U.S. Patent No. 4,063,064 by Saunders et al.; and in U.S. Patent No. 4,088,864 by Theeuwes et al. Passageways comprising controlled-release dimensions sized, shaped and adapted as a releasing-pore formed by aqueous leaching to provide a releasing-pore of a controlled-release rate are disclosed in U.S. Patent Nos. 4,200,098 and 4,285,987 by Ayer and Theeuwes.

Drawing Figure 4 illustrates dosage form 10 in operation during a drug 14 delivery period. The illustrated dosage form 10 comprises an outer wall 12 and an inner wall 16. The outer wall 12 maintains its physical and chemical integrity throughout the drug delivery period. Inner wall 16 comprises a pore former 29 that is aqueous soluble at an osmotic pressure of 8 atmospheres, which 8 atmospheres generally is the osmotic pressure of the gastrointestinal tract of a human. The pore former 29, in one manufacture, is a pharmaceutically acceptable polymer that exhibits an aqueous solubility which is sensitive to osmotic pressure, which polymer is soluble at low osmotic pressure and insoluble or slowly soluble at higher osmotic pressure. Representative of other acceptable pore formers include alkali metal salts such as lithium carbonate, sodium chloride, potassium chloride, and potassium sulfate; alkaline earth metal salts such as calcium phosphate, and calcium nitrate; transition metal salts such as ferric chloride, ferrous sulfate, and zinc sulfate; polysaccharides including mannitol, mannose, galactose, aldohexose, altrose, talose and sorbitol. The osmotic pressure can be measured by Model 302B, Vapor Pressure Osmometer, manufactured by the Hewlett Packard, Co., Avondale, Pennsylvania. A pore forming polymer is

represented by hydroxypropylcellulose possessing a weight-average molecular weight of 80,000 grams per mole. Dosage form 10, when initially placed into an aqueous environment, or into a fluid biological environment, exhibits a slow drug delivery until pore former 29 dissolves or is leached from inner wall 16. For example, after a period of time, often 1 to 2 hrs, the osmotically-sensitive pore former 29 begins to dissolve and is eluted from inner wall 16. This operation, provides a continuous and seamless inner pore wall 16 with pore former 29 being hydrodynamically and osmotically pumped as seen by multi-arrows 30 from dosage form 10. The eluted pore former 29 causes the permeability of inner wall 16 to increase, which correspondingly causes the net permeability of bilaminated inner wall 16-outer wall 12 to increase over time. This unexpected result provided by this invention, with its increase in permeability offsets any decrease in osmotic activity and produces a linear drug delivery profile. The permeability of a wall can be measured according to a procedure which involves measuring the flow of water through the membrane as a result of osmotic driving force. The measurement is first conducted with a single layer membrane which represents the exterior wall, then the measurements are conducted with bilayer membranes with the exterior and interior walls in parallel arrangement. First, an exterior wall membrane is clamped in a vertical orientation between the two chambers which are commonly referred to as Franz cells. One chamber is filled with distilled water which has an osmotic pressure of zero while the adjoining chamber is filled with a solution of known osmotic pressure, such as a saturated solution of potassium chloride which has an osmotic pressure of 245 atmospheres or of saturated lactose solution which has an osmotic pressure of 20 atmospheres. The osmotic pressure of such osmotic reference solutions are measured using standard freezing point depression measurements or vapor pressure osmometry. Vapor pressure osmometers are available, for example, from Knauer & Co GMBH, Berlin, West Germany. The membrane is thus exposed on one side to pure water and exposed to the osmotic reference solution on the opposite side. Prior to making measurements, a graduated pipette is attached to the chamber holding the

osmotic reference solution. Both chambers also contain magnetic stirrers and both chambers are also immersed in a thermal jacket. While measurements are taken, both cells are stirred by way of an external magnetic stirrer and both are maintained at a fixed temperature. The fixed temperature is maintained by continuously passing a thermostated fluid, such as water at 37° centigrade, through the thermal jacket. The Franz cells and stirring equipment are available from Crown Glass Company, Somerville, New Jersey.

Water is imbibed by osmosis from the pure water side through the membrane to the solution side. The rate of water flowing through the membrane is measured by monitoring the volumetric flow as a function of time as reflected in the rise in column of solution within the graduated pipette. The thickness and exposed surface area of the membrane are also measured. These dimensional measurements are performed with standard measuring instruments such as with calipers or a tool maker's microscope. Then, given the volumetric flow rates and these measurements, the osmotic permeability of the external wall,  $K_e$ , is calculated according to the following Equation as:

$$K_e = \frac{(dV/dt) h_e}{\Pi A} \quad (1)$$

where  $(dV/dt)$  = volumetric flow rate

$h_e$  = membrane thickness of the exterior wall

$\Pi$  = osmotic pressure

$\Pi$

$A$  = membrane area

After the permeability of the exterior wall is determined, the bilayer membrane is then mounted in the Franz cell. The bilayer wall is oriented such that the interior wall faces the osmotic reference solution and the exterior wall faces the pure water reference. The osmotic water flux is then

measured across the bilayer membrane according to the above procedures. The osmotic water flux is inversely proportion to the series resistance provided by the exterior wall and the interior wall and directly proportional to the osmotic pressure, as described by Equation 2:

$$dV/dt = \frac{\Pi}{(h_e/K_e A) + (h_i/K_i A)}$$

(2)

where  $h_e$  = thickness of exterior wall

$K_e$  = permeability of exterior wall

$h_i$  = thickness of interior wall

$K_i$  = permeability of interior wall

Rearranging Equation 2 yields the permeability of the interior wall, Equation 3:

$$K_i = \frac{h_i(dV/dt)}{[\Pi A + (h_e/K_e) (dV/dt)]}$$

(3)

Given the measured values of volumetric flow rate, thicknesses of the interior wall and exterior wall, the known value for the permeability of the exterior wall, and measured osmotic pressure, the permeability of the interior wall is then calculated from Equation 3. Osmotic reference values of various values ranging from 0 as represented by distilled water to 445 atmospheres as represented by saturated aqueous urea solution can be tested in this format to characterize the effect of osmotic pressure on the permeability of the bilayer membrane wall. In addition to osmotic pressure, the effect of ionic strength on the permeability of the bilayer wall can be measured. The measurements, in this instance, performed with reference solutions of known ionic strength against the distilled water reference as above. The ionic

strength of the solution,  $\mu$ , can be calculated according to standard equations of physical chemistry such as Equation 4:

$$\mu = 0.5 [C_1 Z_1^2 + C_2 Z_2^2 + C_3 Z_3^2 + \dots]$$

(4)

where  $C_x$  represents the molar concentration of any ion x in the solution and  $Z_x$  represents the corresponding valence of ion x. Reference solutions of a simple salt such as sodium chloride can be prepared as the ionic strength reference. Since the value of each ionic charge Z is unity for sodium chloride, a value of one for the sodium ion and a value of one for the chloride ion, the ionic strength according to Equation 4 is directly proportional to molar concentration. A saturated solution of sodium chloride consists of 5.5 moles per liter and therefore has an ionic strength of 5.5 moles per liter. Such a saturated solution can be serially diluted with distilled water to produce a series of ionic strength reference solutions of any value less than 5.5 moles per liter for use in the reference cell to determine the effect of ionic strength on bilayer permeability as a function of ionic strength.

Pore forming materials which have solubilities sensitive to osmotic pressure or to ionic strength can be screened experimentally prior to formulating them as pore formers within the interior wall. This procedure involves forming an aqueous solution of the candidate pore former using distilled water as the solvent. Then, the resulting solution is cast onto a smooth inert surface, such as a glass plate, and allowed to dry to a film. The film is then removed and cut into sections of known area, thickness, and weight. The resulting film samples are then placed in a series of reference solutions of various osmotic pressures or ionic strengths with mild stirring. The time required for the film to dissolve, t, is then measured as a function of osmotic pressure or ionic strength. Then, given the known values of initial film thickness,  $h_i$ , the dissolution rate of the film,  $dh/dt$ , can be calculated according to Equation 5. The factor 2 is introduced to account for simultaneous dissolution from both sides of the film.

$$dh/dt = h/2t$$

(5)



This screening can also be expanded to include the effect of molecular weight of the pore former on dissolution rate as a function of osmotic pressure or ionic strength. This can be accomplished by determining the dissolution rate of low molecular weight and high molecular weight pore formers which effect generally follows the trend of faster dissolution rate at lower molecular weight and faster dissolution rate at lower osmotic pressure.

Drawing Figure 5 demonstrates the dissolution behavior in the presence of osmotic pressure. The x-axis refers to the osmotic pressure of the test media and the y-axis represents the dissolution rate of pore former under the influence of osmotic pressure. The different symbols represent different molecular weight pore formers initially present within an internal wall. The dark circle represents 80,000 g/mole, the clear circle 190,000 g/mole, the dark triangle 300,000 g/mole, and the clear triangle 1,000,000 g/mole.

#### **DESCRIPTION FOR MANUFACTURING THE COMPOSITION AND DOSAGE FORM OF THE INVENTION**

The interior wall 16 and the exterior wall 12 of the dosage form can be formed by using an air suspension procedure. This procedure consists in suspending and tumbling a wall-forming composition in a current of air and wall-forming composition until a wall is applied to the drug-forming compositions. The interior wall is formed first followed by the exterior wall. The air suspension procedure is well-suited for independently forming an individual wall. The walls can be formed with a wall-forming composition in a Wurster® air suspension coater. The interior wall can be formed using the solvent ethanol. The exterior wall is formed using an organic solvent, such as acetone-water cosolvent 90:10 to 100:0 (wt:wt) and with 2.5 wt% to 7 wt% polymer solvents. An Aeromatic® air suspension coater can be used for applying both the walls, the interior wall and the exterior wall in successive applications.

Other forming technologies, such as pan coating, can be used for providing the dosage form. In the pan coating system, wall-forming compositions are deposited by successive spraying of the composition or the bilayered wall-arrangement, accompanied by tumbling in a rotating pan. A larger volume of cosolvent can be used to reduce the concentration of polymer solids to produce a thinner wall. Finally, the walls of the coated compartments are laser or mechanically drilled, and then dried in a forced air or humidity oven for 1 to 3 days or longer to free the solvent from the dosage form. Generally, the walls formed by these technologies have a thickness of 2 to 20 mils (0.051 to 0.510 mm) with a presently preferred thickness of 2 to 10 mils (0.051 to 0.254 mm).

The dosage form of the invention in another embodiment is manufactured by standard manufacturing techniques. For example, in one manufacture the beneficial drug and other ingredients comprising a therapeutic composition or comprising the drug layer facing the exit means are blended, or the ingredients are blended then pressed, into a solid layer. The drug and other ingredients can be blended with a solvent and formed into a solid or semisolid formed by conventional methods such as ball-milling, calendaring, stirring or roll-milling and then pressed into a selected shape. The drug layer possesses dimensions that correspond to the internal dimensions of the area the drug layer is to occupy in the dosage form. Next, the drug layer is placed in contact with the push-displacement layer prepared in a like manner. The layering of the drug layer and the push-displacement layer can be fabricated by conventional press-layering techniques. The bilayers possess dimensions corresponding to the dimensions of the internal compartment of the dosage form. Finally, the two-layer compartment forming members are surrounded and coated with an inner and outer walls. A passageway is laser drilled or mechanically drilled through the walls to contact the drug layer, with the dosage form optically oriented automatically by the laser equipment for forming the passageway on the preselected drug surface.

5 In another manufacture, the dosage form is manufactured by the wet granulation technique. In the wet granulation technique the drug and the ingredients comprising the drug layer are blended using a solvent, such as isopropyl alcohol as the granulation fluid. Other granulating fluid, such as water, or denatured alcohol 100% can be used for this purpose. The ingredients forming the drug layer are individually passed through a 40 mesh screen and then thoroughly blended in a mixer. Next, other ingredients comprising the layer are dissolved in a portion of the granulation fluid, such as the solvent described above. Then, the latter prepared wet blend is slowly added to the drug blend with continual mixing in the blender. The granulating fluid is added until a wet blend mass is produced, which wet mass is then forced through a 20 mesh screen onto oven trays. The blend is dried for 18 to 24 hours at 25°C to 40°C. The dry granules are then screened with a 16 mesh screen. Next, a lubricant is passed through a 60 mesh screen and added to the dry screened granule blend. This procedure is followed for the push-displacement composition. The granulation in both instances, are put into mixing containers and tumble mixed for 2 to 10 minutes. The drug and the push composition are layered and pressed into a layered tablet, for example in a Manesty® layer press.

20 Another manufacturing process that can be used for providing the drug and push-displacement compositions comprise blending their powdered ingredients in a fluid bed granulator. After the powdered ingredients are dry blended in the granulator, a granulating fluid, for example, poly(vinylpyrrolidone) in a solvent, such as in water, is sprayed onto the respective powders. The coated powders are then dried in a granulator. This process coats the ingredients present therein while spraying the granulating fluid. After the granules are dried, a lubricant, such as stearic acid or magnesium stearate, is blended as above into the mixture. The granules are then pressed in the manner described above. In another embodiment, when the fluid in granulating process is used to manufacture the push-displacement layer, an antioxidant present in the polyalkylene oxide can be removed during the processing step. If antioxidant is desired, it can be added to the push-

displacement layer, and this can be accomplished during the fluid bed granulation described above.

5 The dosage form of this invention is manufactured in another embodiment by mixing a drug with composition-forming ingredients and pressing the composition into a solid layer possessing dimensions that correspond to the internal dimensions of the compartment space adjacent to a passageway. In another embodiment, the drug and other drug composition forming ingredients and a solvent are mixed into a solid, or semi-solid, by conventional methods such as ball-milling, calendaring, stirring, or roll-milling, and then pressed into a preselected, layer-forming shape.

10 In the general manufactures as presented herein, the manufacture comprising a drug and compositional forming ingredients are placed in contact with the push-displacement layer, and the drug layer and the push layers are surrounded then with the bilayered walls. The layering of the drug composition and the push-displacement composition can be accomplished by using a conventional two-layer tablet press technique. The walls can be applied by molding, spraying or dipping the pressed shapes into wall-forming materials. Another technique that can be used for applying the walls is the air-suspension wall-forming procedure. This procedure consists in  
15 suspending and tumbling the two layered drug-push core in a current of air until the wall-forming composition are applied separately to the compartment drug-push layers. Manufacturing procedures are described in Modern Plastics Encyclopedia, Vol. 46, pp. 62-70 (1969); and in Pharmaceutical Sciences, by Remington, 14th ed., pp. 1626-1648 (1970) published by Mack  
20 Publishing Co., Easton, PA. The dosage form can be manufactured by following the teaching the U.S. Patent Nos. 4,327,725; 4,612,008; 4,783,337; 4,863,456; and 4,902,514.

### DETAILED DISCLOSURE OF EXAMPLES

30 The following examples are merely illustrative of the present invention and they should not be considered as limiting the scope of the invention in

any way, as these examples and other equivalents thereof will become apparent to those versed in the art in the light of the present disclosure and the accompanying claims.

### EXAMPLE 1

The solubility of pore former candidates to osmotic pressure was evaluated. First, aqueous solutions of the pore former candidate hydroxypropylcellulose commercially-available from Hercules, Wilmington, Delaware, under the trade name Klucel® were prepared using grades of different molecular weights. The solutions were prepared with molecular weights of 80,000 grams per mole, 300,000 and 1 million grams per mole using Klucel EF, GF and HF, respectively. An intermediate molecular weight of 190,000 grams per mole was also generated by blending equal weight portions of the EF and GF grades. The resulting solutions were then cast on glass plates and dried at room temperature. The resulting films were removed from the plates and a discs of 2.4 cm<sup>2</sup> area were punched from the films. Thicknesses of the discs were measured with a table micrometer. Four discs of each molecular weight type were then individually bagged in nylon mesh bags having 12 openings per inch and attached to a plastic rod. The discs were then immersed in individual solutions of the nonionic sugar, sorbitol, at concentrations of 0, 182, 274, and 547 mg per milliliter thermostated to 37 degrees centigrade corresponding to a series of osmotic pressure values of 0, 30, 48, and 125 atmospheres, respectively, and oscillated with a frequency of 30 cycles per minute at an amplitude of 2 centimeters. The experiment was conducted in 4 by 4 experimental matrix such that each molecular weight type was tested in each osmotic pressure reference. The time to dissolution was then monitored for each sample. Dissolution rate was calculated according to Equation 5 and plotted as a function of osmotic pressure for each molecular weight. The data are plotted in Figure 5. Based on these measurements, it was determined that the hydroxypropylcellulose having the lowest molecular weight of the series is

insoluble above 30 atmospheres and soluble at an osmotic pressure between 0 and 30 atmospheres. This candidate pore former was used in subsequent membrane formulations of the osmotically-sensitive interior wall of bilayer membranes of the invention.

### EXAMPLE 2

A novel, therapeutic composition comprising hydromorphone and acetaminophen, wherein the hydromorphone is a member selected from the group consisting of hydromorphone pharmaceutically acceptable base and hydromorphone pharmaceutically acceptable salt is prepared as follows: first, 175 g of hydromorphone hydrochloride, 500 g of acetaminophen, 647.5 g of poly(ethylene oxide) possessing a 100,000 molecular weight, and 43.75 g of poly(vinylpyrrolidone) having an average molecular weight of 40,000 are added to a mixing bowl and the ingredients dry mixed for 10 minutes. Then, 331 g of denatured, anhydrous alcohol is added slowly to the blended ingredients with continuous blending for 10 minutes. Next, the freshly prepared granulation is passed through a 20 mesh screen, allowed to dry at 25°C for about 20 hours, and then passed through a 16 mesh screen. Next, the granulation is transferred to a mixer, and lubricated with 8.75 g of magnesium stearate to produce a therapeutic hydromorphone acetaminophen composition. The therapeutic composition is compressed into tablets comprising 35 mg of hydromorphone hydrochloride and 100 mg of acetaminophen. The tablets are compressed under 2 tons of pressure.

### EXAMPLE 3

The hydromorphone-acetaminophen analgesic tablets are coated with an interior wall then coated by an exterior wall as follows: first, 154 g of ethyl cellulose having a molecular weight of 220,000 grams per mole and an ethoxyl content of 48.0 to 49.5 weight percent, and 112 g of hydroxypropylcellulose having a 80,000 molecular weight and a molar

substitution of 3, and then 14 g of polyoxyethylene (40) stearate were dissolved with stirring in 3,720 g of anhydrous ethanol. The solution resulting was allowed to stand without stirring for 3 days, to provide the interior wall-forming composition. Next, the exterior wall forming composition was prepared by dissolving 162.5 g of cellulose acetate having an acetyl content of 39.8 wt% and a molecular weight of 40,000 grams per mole, and 87.5 g of ethylene oxide-propylene oxide-ethylene oxide triblock copolymer having a molecular weight of approximately 8,400 grams per mole and an ethylene oxide content of 82 wt% in 4,750 g of anhydrous acetone with stirring and slight warming to 26°C. The resulting exterior forming wall composition was allowed to stand at ambient room temperature for one day.

Next, the analgesic tablets are placed into a pan coater. The interior wall-forming solution was sprayed onto the tablets in a current of warm air until a wall with a thickness of 6 mils (0.152 mm) was applied to the tablets. The interior ethylcellulose-hydroxypropylcellulose wall coated tablets were dried in a forced air oven at 40°C for 24 hrs. Then, the interior coated tablets were returned to the pan coater and the exterior wall forming coat was sprayed onto the interior coated tablet to a thickness of 3 mils (0.0762 mm). Next, the biwalled tablets were dried and a round exit port having a diameter of 30 mils (0.762 mm) was drilled through the biwalls to provide a controlled-extended release dosage form.

#### EXAMPLE 4

Therapeutic compositions are manufactured by following the procedure of Example 2, to provide analgesic compositions comprising 1 mg to 1000 mg of an opioid selected from the group consisting of hydromorphone, hydromorphone base, hydromorphone salt, and hydromorphone derivatives; at least one nonopioid analgesic of 1 to 1000 mg selected from the group consisting of acetaminophen, aspirin, flurbiprofen, ibuprofen, indoprofen, benoxaprofen, propoxyphene, salicylamide, zenazocine and zomepirac; with the dose of opioid and nonopioid analgesic in the composition comprising 2

mg to 1000 mg; at least one polymeric carrier for both the opioid and nonopioid analgesics selected from 10 mg to 500 mg of a poly(alkylene oxide) comprising a 100,000 to 500,000 molecular weight represented by poly(methylene oxide), poly(ethylene oxide), poly(propylene oxide), poly(isopropylene oxide) and poly(butylene oxide); or a polymeric carrier of 10 mg to 500 mg of a carboxymethylene having a 7,500 to 325,000 molecular weight represented by a member selected from the group consisting of an alkali carboxymethylcellulose, and potassium carboxymethylcellulose, calcium carboxymethylcellulose, and potassium carboxymethylcellulose; 0.5 mg to 50 mg of a poly(vinyl) polymer possessing a 5,000 to 300,000 molecular weight as represented by poly(vinyl pyrrolidone), copolymer of poly(vinyl pyrrolidone and vinyl acetate), copolymer of poly(vinyl pyrrolidone and vinyl chloride), copolymer of vinyl pyrrolidone and vinyl fluoride, copolymer of poly(vinyl pyrrolidone and vinyl butyrate), copolymer of poly(vinyl pyrrolidone and vinyl laurate) and copolymer of poly(vinyl pyrrolidone and vinyl stearate); and 0 to 7.5 mg of a lubricant represented by a member selected from the group consisting of polyethylene glycol magnesium stearate, calcium stearate, potassium oleate, sodium stearate, stearic acid, and sodium palmitate. The therapeutic opioid-nonopioid dual analgesic composition may contain other composition forming ingredients, for example, colorants, compression aids such as microcrystalline cellulose, and binders such as starch. The analgesic composition can be compressed at a 1/8 to 3 ton-force to yield an orally administrable tablet.

#### **EXAMPLE 5**

The therapeutic analgesic composition is manufactured into an extended-sustained-linear release dosage form by providing the analgesic composition with an interior wall, an exterior wall and a passageway as set forth in Example 2.

#### **EXAMPLE 6**



A novel and useful therapeutic composition comprising 432 g of a morphine selected from the group consisting of morphine base, morphine pharmaceutically acceptable salt, pharmaceutically acceptable inorganic salt, pharmaceutically acceptable organic salt, morphine hydrobromide, morphine hydrochloride, morphine mucate, morphine N-oxide, morphine sulfate, morphine acetate, morphine phosphate dibasic, morphine phosphate monobasic, morphine inorganic salt, morphine organic salt, morphine acetate trihydrate, morphine bi(heptafluorobutyrate), morphine bi(methylcarbamate), morphine bi(pentafluoropropionate), morphine bi(pyridine-3-carboxylate), morphine bi(trifluoroacetate), morphine bitartrate, morphine chlorhydrate, and morphine sulfate pentahydrate, and 600 g of an analgesic selected from the group consisting of acetaminophen, aspirin, benoxaprofen, flurbiprofen, ibuprofen, indoprofen, propoxyphene, salicylamide, zenazocrine and zomepirac are blended with 963 g of poly(alkylene oxide) comprising a 300,000 molecular weight and 90 g of poly(vinyl pyrrolidone) having an average molecular weight of 40,000 are added to a mixing bowl and dry mixed for 12 minutes. Next, 404 g of denatured, anhydrous alcohol is slowly added to the blended composition forming materials with continuous mixing for 15 minutes. Then, the prepared granulation is passed through a 20 mesh screen, and allowed to dry at 25°C for 18 hrs, and then passed through a 16 mesh screen. The screened granulation is transferred to a planetary mixer, and with constant blending 14.9 g of calcium stearate is added to produce the therapeutic two analgesic composition. The composition is compressed into tablets comprising 350 mg of the therapeutic composition consisting of 70 mg of opioid analgesic and 100 mg of nonopioid analgesic and 180 mg of tablet forming materials. The tablets are compressed under 2.5 tons of pressure to provide a sustained release analgesic tablet.

#### EXAMPLE 7

The therapeutic compositions provided above and comprising the opioid analgesic and the nonopioid analgesic are coated with a biwall comprising an interior wall, and exterior wall and an exit passage by following the procedure of Example 2 to provide a controlled-linear-extended zero-releasing dosage form indicated for the management of pain.

### **EXAMPLE 8**

A controlled release dosage form for once a day administration of the potent opioid analgesic, morphine, was fabricated as follows: First, 350 grams of morphine sulfate hexahydrate, 585 grams of polyoxyethylene having a molecular weight of approximately 200,000 grams per mole, and 60 grams of polyvinyl pyrrolidone having a molecular weight of 40,000 grams per mole were each passed through a stainless screen having 40 wires per inch and then dry mixed. Anhydrous ethanol was added with mixing until a uniform damp mass formed. The damp mass was forced through a screen having 20 wires per inch, forming granules which were then air dried at 22.5°C overnight. After drying the granules were passed again through the 20 mesh screen forming free-flowing granules. Then, 4.5 grams of magnesium stearate and 0.5 grams of butylated hydroxytoluene were passed through a screen with 60 wires per inch into the granules. The resulting mixture was tumbled for 5 minutes to form a homogenous blend, to produce a drug granulation.

In a separate process, 936.7 grams of polyoxyethylene having a molecular weight of approximately 7 million grams per mole, 50 grams of hydroxypropyl methyl cellulose having a molecular weight of 11,300 grams per mole and a hydroxypropyl content of 10 weight percent and a methoxyl content of 29 weight percent, were individually passed through a screen with a size of 40 wires per inch. Then, 10 grams of ferric oxide green and 0.8 grams of butylated hydroxytoluene were passed through a screen with 60 wires per inch into the bulk mixture. The resulting powders were mixed to a uniform blend. Then, anhydrous ethanol was added with mixing to produce a

uniform damp mass. The damp mass was then forced through a screen with 20 wires per inch and air dried at ambient room conditions, 22°C, overnight. The dried granules were then forced through the 20 mesh screen. Finally, 2.5 grams of magnesium stearate, 0.8 grams of butylated hydroxytoluene were passed through a screen with 60 wires per inch into the granules. The mixture was tumble mixed for 3 minutes to produce a push-displacement composition.

Next, bilayer tablets, comprising the morphine composition, and the push-displacement composition, were compressed on a bilayer-tablet press with the above granulations using a 13/32 inch (10.3 mm) round tooling punch. First, 287 mg of drug granulation was fed into the die cavity and lightly compacted. Then, 151 mg of the push granulation was added to the die cavity and laminated to the push layer with a force of 0.4 tons. Each of the resulting tablets contained a unit doses of 100 mg morphine sulfate pentahydrate.

Next, the bilayer cores, prepared immediately above, were then coated with the laminated membrane of this invention according to the following procedures: First, 154 grams of ethyl cellulose having a molecular weight of approximately 220,000 grams per mole and an ethoxyl content of 48.0 to 49.5 weight percent, 112 grams of hydroxypropyl cellulose having a molecular weight of 80,000 and a molar substitution of 3 and 14 grams of polyoxyethylene (40) stearate was dissolved in 3,720 grams of anhydrous ethanol formula with stirring. The resulting solution was allowed to stand without stirring for 3 days. This solution is referred to as the interior wall forming solution. A second solution was prepared by dissolving 162.5 grams of cellulose acetate having a acetyl content of 39.8 weight percent and an approximate molecular weight of 40,000 grams per mole and 87.5 grams of ethylene oxide-propylene oxide-ethylene oxide triblock copolymer having molecular weight of approximately 8,600 grams per mole and an ethylene oxide content of 82 weight percent in 4,750 grams of anhydrous acetone with stirring and slight warming to 26 degrees centigrade. The resulting solution is

the exterior-wall forming solution and it was allowed to stand at ambient room temperature for one day.

5 The tablets were then charged into a pan coater. The interior-wall forming solution was sprayed onto the tablets in a current of warm air until a coating thickness of 9 mils was applied. The coating solution was stirred continuously while the tablets were being coated. The coated tablets were then removed from the coating pan and dried in a forced air oven thermostated to 40 degrees centigrade for a day. Then, the tablets were returned to the pan and the exterior wall forming solution was sprayed onto 10 the dried tablets until a coating thickness of 3 mils was applied. The exterior wall forming solution was stirred continuously during the coating process. After coating the tablets were removed from the coater and a delivery orifice was drilled through the laminated walls with a drill bit producing one round port having a diameter of 25 mils in the center of the drug layer side of the 15 tablet. The drilled systems were then placed in a forced air drying oven thermostated to 50 degrees centigrade for 3 days which drying completed the fabrication of the dosage form.

The dose release performance of the dosage forms prepared according to this example were ascertained by measuring the dose release in 20 distilled water at 37°C and as seen in the delivery pattern of drawing Figure 6. The measured results indicated a linear profile over 12 hrs at a constant rate of release of about 6 mg/hr during the corresponding time period.

The dosage form prepared according to this example with the results depicted in Figure 6 comprises: a drug layer composition comprising 35 wt% 25 morphine sulfate pentahydrate, 58.50 wt% poly(ethylene oxide) possessing a 200,000 molecular weight, 6 wt% poly(vinyl pyrrolidone) of 40,000 molecular weight, 0.45 wt% magnesium stearate, and 0.05 wt% butylated hydroxytoluene; a push-displacement composition comprising 93.67 wt% poly(ethylene oxide) possessing a 7,000,000 molecular weight, 5 wt% 30 hydroxypropylmethylcellulose possessing a 11,200 molecular weight, 1 wt% green ferric oxide, 0.25 wt% magnesium stearate, and 0.08 wt% butylated hydroxytoluene; an interior wall comprising 55 wt% ethylcellulose possessing

5 a viscosity of 100 centipoises, 40 wt% hydroxypropyl-cellulose of 80,000  
molecular weight, and 5 wt% Myrj 52S manufactured by ICI Americas, Inc.,  
Wilmington, Delaware which represents polyoxyethylene (40) stearate; an  
exterior wall comprising 65 wt% cellulose acetate possessing a 39.8% acetyl  
content, and 35 wt% Pluronic F68 manufactured by BASF Corporation, Mt.  
Olive, New Jersey, which represents a triblock copolymer of ethylene oxide-  
propylene oxide-ethylene oxide having a molecular weight of approximately  
8,400 grams per mole with approximately 82 weight percent ethylene oxide  
content; a nominal time to deliver 80% of dose of 15.7 hrs; a mean release  
10 rate of 6.4 mg/hr; an exit port of 25 mil (0.635 mm), and a dose of drug of 100  
mg; with the drug composition weighing 287 mg; the push-displacement  
composition 151 mg, the interior wall 80.1 mg; and the exterior wall 26.9 mg;  
the interior wall was 8.8 mil (0.224 mm) thick and the exterior wall 2.6 mil  
(0.066 mm) thick.

#### EXAMPLE 9

The present example is provided to illustrate the unexpected results  
obtained by this example. The dosage form of this example comprises a  
single wall. The dosage form drug composition comprises the identical core  
composition as specified in Example 8 which is 35 wt% morphine sulfate  
pentahydrate, 58.50 wt% polyethylene oxide possessing a 200,000 molecular  
weight, 6 wt% polyvinyl pyrrolidone possessing a 40,000 molecular weight,  
0.45 wt% magnesium stearate, and 0.05 wt% butylated hydroxytoluene; a  
push-displacement composition comprising 93.97 wt% polyethylene oxide  
25 possessing a 7,000,000 molecular weight, 5 wt%  
hydroxypropylmethylcellulose possessing a 11,200 molecular weight, 1 wt%  
green ferric oxide, 0.25 wt% magnesium stearate, and 0.08 wt% butylated  
hydroxytoluene; a single wall comprising 92.0 wt% cellulose acetate  
possessing a 39.8% acetyl content, and 8 wt% polyethylene glycol  
30 possessing a 3350 molecular weight; and a mean release rate of 6.6 mg/hr.  
The single wall was formed from 80:20(v:v) methylene oxide: methanol. The

results disputed in drawing Figure 7 indicated the dosage form delivered drug for 16 hours at a nonzero order continuously declining rate.

#### **EXAMPLE 10**

5

10

15

20

25

30

The procedure set forth above was followed to manufacture a dosage form with a drug composition comprising 35 wt% morphine sulfate pentahydrate, 58.5 wt% polyethylene oxide possessing a 200,000 molecular weight, 6.0 wt% polyvinyl pyrrolidone of 40,000 molecular weight, 0.45 wt% magnesium stearate, and 0.05 butylated hydroxytoluene; a push-displacement composition comprising 93.97 wt% polyethylene oxide possessing a 7,000,00 molecular weight, 5.0 wt% hydroxypropylmethylcellulose possessing a 11,200 molecular weight, 1 wt% green ferric oxide, 0.25 wt% magnesium stearate, and 0.08 wt% butylated hydroxytoluene; an inside wall comprising 55 wt% ethyl cellulose having an ethoxyl content in the range of 48.0 to 49.5 weight percent and a viscosity of 100 centipoise as a 5 percent solution at 25° centigrade in 80:20 toluene:ethanol, 20 wt% hydroxypropylcellulose of molecular weight 80,000 grams per mole as supplied as Klucel® EF manufactured by Hercules Inc., Wilmington, Delaware, 20 wt% Kollidon 12 PF polyvinylpyrrolidone manufactured by BASF, Ludwigshafen, West Germany, and 5 wt% Myrj 52S of approximately 2,060 grams per molecular weight (see Example 8); an outside wall comprising 65 wt% cellulose acetate having a 39.8% acetyl content, and 35 wt% Pluronic F68 (see Example 8); one 25 mil (0.635 mm) exit; and a mean release rate of 6.4 mg/hr. The dosage form provided by this example exhibits the drug release profile seen in Figure 8. The dosage form delivers drug at substantially zero order rate earlier than the dosage form disclosed in Example 4 and its delivery profile attributed to the increase of pore forming polyvinyl pyrrolidone in the interior wall.

#### **EXAMPLE 11**

The present example provide a delivery system for delivering a narcotic analgesic manufactured according to the examples set forth above, with the drug delivered from the present example a member selected from the group consisting of oxymorphone, hydromorphone, metopon, hydrocodone, levorphanol, phenazocine, methodone, dextromoramide, dipipanone, phenadoxone, codeine, dihydrocodeine, oxycodone, pholcodine, meperidine, levorphanol, phenazocine, methadone, dextromoramide, dipanone, phenodozone, meperidine, alphaprodine, anileridine, and pimiondone.

### EXAMPLE 12

An osmotic dosage form designed to deliver morphine at extended zero order rate was fabricated as follows. 330 grams of morphine sulfate hexahydrate and 610 grams of mannitol were dry blended and then passed through a screen with 40 wires per inch into the bowl of a planetary mixer. 50 grams of polyvinyl pyrrolidone having a molecular weight of 9,000 grams per mole was dissolved with stirring in 500 milliliters of anhydrous ethyl alcohol to form a binder solution. The binder solution was added slowly to the powders as they were mixed in the planetary mixer until a damp mass was formed. The damp mass was then passed through a screen with 20 wires per inch. The resulting extrusions were air dried overnight at room temperature and then passed again through a 20 mesh screen, thereby forming free-flowing granules. 10 grams of magnesium stearate sized through a 60 mesh screen was then tumble mixed into the granules producing the finished granulation. The resulting granulation was compressed with a force of 1.5 tons using with 11/32 round standard concave tooling at a tablet weight 304 mg. Each tablet contained a unit dose equivalent to 100 mg of morphine sulfate hexahydrate.

The tablets were then coated with an interior wall consisting of 55 parts by weight of ethylcellulose having a molecular weight of 220,000 grams per mole, 30 parts by weight of hydroxypropyl cellulose having a molecular weight of 80,000, 5 parts by weight of hydroxypropyl cellulose having a molecular weight of 300,000, 5 parts of polyvinyl pyrrolidone molecular weight having a molecular weight of 1,300 grams per mole and 5 parts of the ethylene oxide-

propylene oxide-ethylene oxide triblock copolymer having a nominal molecular weight of 7,700 grams per mole with 72 weight percent of ethylene oxide supplied by BASF Corporation as Pluronic F87. This composition was applied from a solution of ethyl alcohol according to the procedures outlined in Example 8 to a thickness of 5 mils. Then, an exterior wall was applied according to the procedures in Example 8 by spray coating 3 mils of 70 parts cellulose acetate having an acetyl content of 39.8 weight percent and 40,000 grams per mole and 30 parts polyethylene glycol having a molecular weight of 400 from a solution of acetone. Two delivery ports were then drilled in the system, one per side, centered in the round dome of the dosage form. Finally, the dosage form was dried for 3 days at 50° centigrade to remove residual coating solvents and establish equilibrium composition of the coating. This resulted in a dosage form which when placed in an aqueous environment generated a internal osmotic pressure of 46 atmospheres which remained constant while solid drug was present within the core. After the last bit of solid drug was dissolved, the osmotic pressure within the core declined to less than 30 atmospheres thereby allowing the pore formers of the internal wall to elute from the wall, thereby increasing wall permeability to compensate for the decreasing in osmotic driving force with the net effect to maintain elevated rate of release of the analgesic for prolonged time.

### EXAMPLE 13

A dosage form which delivers the analgesic hydromorphone for once daily administration was fabricated as follows: 28.6 grams of hydromorphone hydrochloride and 50 grams of polyvinyl pyrrolidone having a molecular weight of 2,500 grams per mole were dissolved with stirring in 500 milliliters of ethyl alcohol. 914 grams of sodium chloride was dried at 50°C in forced air overnight and then was passed through a sieve with 40 wires per inch into a planetary mixer. The solution of drug was then slowly added to the sodium chloride powder with stirring to form a uniform damp mass. Two washings of ethanol were performed to complete the quantitative transfer of the drug into



the damp mass. The damp mass was then passed through a mesh with 20 wires per inch, spread on a tray, and then oven dried overnight in forced air at 40°C. The dried material was then passed through a screen with 20 wires per inch, forming a free flowing mixture. Finally, 7 grams of stearic acid was passed through a screen with 80 wires per inch into the bulk mixture and tumble mixed for 3 minutes, completing the granulation. The resulting granulation was compressed at a force of 2 tons using 3/8 inch (9.5 mm) diameter round tooling at a tablet weight of 280 milligrams. Each tablet contained a unit dose of 8 milligrams of the analgesic.

The tablets were then coated with an interior wall composition consisting of 55 parts of ethylcellulose having a molecular weight of approximately 118,000 grams per mole and an ethoxyl content of 48.0-49.5 weight percent, 40 parts of the osmotically-sensitive pore former methyl cellulose having a molecular weight of approximately 10,400 grams per mole as supplied by the Dow Chemical Company, Midland, Michigan in Methocel™ A5, and 5 parts polyoxyethylene (50) stearate. The coating fluid to apply this composition was prepared by dissolving the ethyl cellulose and the polyoxyethylene (50) stearate in ethyl alcohol and then dispersing the methyl cellulose in the resulting solution. The resulting fluid was spray coated according to the procedures in Example 8 to a wall thickness of 6 mils. Then, the exterior wall consisting of 85 parts cellulose acetate with an acetyl content of 39.8 weight percent and a molecular weight of approximately 50,000 grams per mole and 15 parts of the ethylene oxide-propylene oxide-ethylene oxide triblock copolymer having a molecular weight of approximately 8,600 grams per mole and a ethylene oxide content of 82 weight percent otherwise referred to as Pluronic F87 were applied from a solution of acetone according to the procedures in Example 8 to a uniform exterior wall thickness of 3 mils. Then, a 15 mil diameter port was laser drilled through both walls in the center of each side of the dosage form. Finally, the residual coating solvents were removed by drying in forced air with 50% relative humidity at a temperature of 50°C for 48 hours followed by four hours at 50°C without humidity.

When placed in an aqueous environment, water is imbibed by osmosis into the dosage form dissolving the drug and salt to produce an internal osmotic pressure of 287 atmospheres and an ionic strength of 5.47 molar which osmotic pressure and ionic strength is maintained while the drug is dispensed until the last remaining portion of sodium chloride dissolves, at which point in time, the sodium chloride dilutes as a result of the water continuing to flow into the dosage form to lower levels of osmotic pressure and ionic strength, thereby allowing the pore former within the interior wall to dissolve and elute from the wall and thus increase permeability of the wall to compensate for the decrease in osmotic pressure as a result of the dilution. The dosage form meters the release of 8 milligrams of the analgesic at controlled rate over prolonged time.

#### EXAMPLE 14

An extended release dosage form of the analgesic hydrocodone for dosing once a day dosing was prepared. 6,000 grams of hydrocodone bitartrate hemipentahydrate and 19,000 grams of the osmotic agent glycine were individually milled to a particle size of less than 420 microns and charged into a fluid bed granulator. Then, a binder solution was prepared by dissolving of 130 grams of hydroxypropyl methylcellulose having a hydroxypropyl content of 10 weight percent, a methoxyl content of 29 weight percent and a molecular weight of 11,300 grams per mole as supply under the product name Methocel E5 manufactured by DOW Chemical Company, Midland, Michigan, in 2,470 milliliters of distilled water with stirring. The powders fluidized in a current of air and then the binder solution was sprayed onto the fluidized powders in a current of warm air until to form granules. The granules were removed from the granulator and transferred to a tote mixer where 30 grams of tablet lubricant, hydrogenated vegetable oil, was passed through a mesh with 60 wires per inch into the bulk granulation. The lubricant was mixed into the bulk by tumbling for 3 minutes. The resulting granulation was compressed with oval tooling at a compression force of 2 tons to an

average tablet weight of 252 milligrams. Each tablet contained a unit dose of 60 milligrams of the analgesic.

The resulting tablets were coated according to the procedures described in Example 8. The interior wall consisted of 60 parts ethylcellulose having an ethoxyl content of 48.0-49.5 with a molecular weight of approximately 78,000 grams per mole, 34 parts hydroxypropyl cellulose having a molecular weight of approximately 80,000 grams per mole, 1 part dibutyl sebacate, and 5 parts polyoxyethylene (8) stearate as supplied in Myrj 45 manufactured by ICA Americas, sprayed from ethyl alcohol to a coating thickness of 6.5 mils. The exterior wall was applied according to the procedures detailed in Example 8. The coating consisted of 90 parts cellulose acetate having an acetyl content of 39.8 weight percent and an average molecular weight of 30,000 grams per mole and 10 parts of ethylene oxide-propylene oxide-ethylene oxide triblock copolymer having an ethylene oxide content of 83 weight percent and a molecular weight of 14,600 grams per mole sprayed from acetone at 2.5 weight percent in the acetone to an exterior wall thickness of 2.5 mils. A 15-mil diameter delivery port was then laser drilled on both sides of the dosage form. Fabrication was completed by drying in a forced air oven at 50°C in forced air for 3 days to remove residual solvents.

When the resulting dosage form was placed in aqueous media, it imbibed water across the bilayer wall coating under the osmotic gradient across the membrane where the internal osmotic pressure was 90 atmospheres was maintained while solid drug and glycine were present, after which point, the osmotic pressure continuously declined in time. This process continued until the internal osmotic pressure declined to below 30 atmospheres at which point the osmotically-sensitive pore former hydroxypropyl cellulose eluted from the interior wall, thereby increasing the permeability to compensate for the continuously decreasing osmotic driving force. The resulting dosage form delivered 60 mg of the analgesic at controlled rate over prolonged time.

**METHOD OF PRACTICING INVENTION**

5 The invention pertains additionally to the use of the therapeutic dosage form by providing a method for delivering a drug orally to a warm-blooded animal including a human patient in need of therapy. The method comprises administering orally the therapeutic dosage form into the patient, wherein the dosage form comprises a therapeutic composition surrounded by an interior wall and a contacting outside wall, or the method comprises administering a dosage form comprising a therapeutic composition and a push composition with both compositions surrounded by an inside wall and an outside wall. The dosage form, in both methods of use, in the gastrointestinal tract imbibes fluid through both wall, generates osmotic energy, that causes the therapeutic composition to be administered through an exit port up to 24 hours to provide controlled and sustained therapy.

10 In summary, it will be appreciated that the present invention contributed to the art an unobvious dosage form that possesses practical utility, and can administer a drug at a dose-metered release rate per unit time. While the invention has been described and pointed out in detail with reference to operative embodiments thereof, it will be understood by those skilled in the art that various changes, modifications, substitution and omissions can be made without departing from the spirit of the invention. It is intended, therefore, that the invention embrace those equivalents within the scope of the claims which follow.

**The Claims:**

1. A therapeutic composition comprising a member selected from the group consisting of hydromorphone and its pharmaceutically acceptable salts, acetaminophen, and a pharmaceutically acceptable polyethylene oxide carrier.
2. The therapeutic composition according to claim 1, wherein the composition comprises polyvinylpyrrolidone.
3. A therapeutic composition comprising a member selected from the group consisting of hydromorphone and its pharmaceutically acceptable salts, acetaminophen, and a pharmaceutically acceptable polyethylene oxide carrier, which composition is coated with a wall comprising ethylcellulose and hydroxypropylcellulose.
4. A therapeutic composition comprising a member selected from the group consisting of hydromorphone and its pharmaceutically acceptable salts, acetaminophen, and a pharmaceutically acceptable polyethylene oxide carrier, which composition is coated with an interior wall comprising ethyl cellulose and hydroxypropylcellulose and an exterior wall comprising cellulose acetate.
5. A therapeutic composition comprising an opioid analgesic and a nonopioid analgesic, wherein the opioid analgesic comprises 0.1  $\mu$ g to 1000 mg of a member selected from the group consisting of hydromorphone and its pharmaceutically acceptable salts, the nonopioid analgesic comprises 1 mg to 1000 mg of a member selected from the group consisting of aspirin, flurbiprofen, ibuprofen, indoprofen, benoxaprofen, propoxphene, salicylamide, zenazocine and zomepirac, and 10 mg to 500 mg of a pharmaceutically acceptable poly(alkylene oxide) carrier.

6. The therapeutic composition according to claim 5, wherein the poly(alkylene oxide) is replaced by a pharmaceutically acceptable carboxyalkylcellulose carrier.

5 7. The therapeutic composition according to claim 5, wherein the composition is coated with a wall comprising ethylcellulose and hydroxypropylcellulose.

10 8. The therapeutic composition according to claim 5, wherein the composition is coated with a wall comprising cellulose acylate.

9. The therapeutic composition according to claim 5, wherein the composition comprises a polyvinylpyrrolidone.

15 10. A therapeutic composition comprising a first analgesic selected from the group consisting of morphine and its pharmaceutically acceptable salts, a second analgesic selected from the group consisting of acetaminophen, aspirin, benoxaprofen, flurbiprofen, ibuprofen, indoprofen, propoxyphene, salicylamide, zenazocine, and zomepirar, and a pharmaceutically acceptable poly(alkylene oxide) carrier.

20 11. The therapeutic composition according to claim 10, wherein the poly (alkylene oxide) is replaced by a pharmaceutically acceptable carrier.

25 12. The therapeutic composition according to claim 10, wherein the composition is coated with a wall comprising ethylcellulose and hydroxypropylcellulose.

30 13. The therapeutic composition according to claim 10, wherein the composition with a wall comprising a cellulose acetate.

14. The therapeutic composition according to claim 10, wherein the composition is a dosage form tablet and comprises 1 mg to 1000 mg of the first analgesic and 1 mg to 1000 mg of the second analgesic.

5 15. A laminate for manufacturing a dosage form, the laminate comprising a lamina comprising ethylcellulose and hydroxypropylcellulose, and a lamina comprising cellulose acetate.

10 16. A dosage form tablet comprising a drug coated with a laminate comprising a lamina comprising ethylcellulose and hydroxypropylcellulose and a lamina comprising cellulose acetate.

15 17. A dosage form tablet comprising a drug, an interior wall in contact with tablet comprising ethylcellulose and hydroxypropylcellulose, and an exterior wall in contact with the interior wall comprising cellulose acetate.

20 18. A dosage form composition comprising 35 wt% morphine sulfate pentahydrate, 58.50 wt% poly(ethylene oxide), 6 wt% poly(vinylpyrrolidone), 0.45 wt% magnesium stearate, and 0.05 wt% butylated hydroxytoluene; and a wall comprising ethylcellulose and hydroxypropylcellulose in contact with the composition, and a wall comprising cellulose acetate distant from the composition.

25 19. A dosage form comprising a drug composition, an expandable composition, an interior wall in contact with both composition comprising an ethylcellulose and a hydroxypropylcellulose, and an exterior wall in contact with the interior wall comprising a cellulose acylate.

30 20. A dosage form comprising a drug layer comprising 35 wt% morphine sulfate pentahydrate, 58.50 wt% polyethylene oxide, 6 wt% polyvinylpyrrolidone, 0.45 wt% magnesium stearate, and 0.05 wt% butylated hydroxytoluene; a push-displacement layer comprising 93.97 wt% polyethylene oxide, 5 wt% hydroxypropylmethylcellulose, 1 wt% ferric oxide,

0.25 wt% magnesium stearate, and 0.08 wt% butylated hydroxytoluene; and a wall surrounding the layers comprising 92 wt% cellulose acetate and 8 wt% polyethylene glycol.

5           21. A dosage form comprising a drug layer comprising 35 wt% morphine sulfate pentahydrate, 58.5 wt% polyethylene oxide, 6.0 wt% polyvinylpyrrolidone, 0.45 wt% magnesium stearate, and 0.05 wt% butylated hydroxytoluene; a push displacement layer comprising 93.97 wt% polyethylene oxide, 5.0 wt% hydroxypropylmethylcellulose, 1 wt% green ferric  
10 oxide, 0.25 wt% magnesium stearate, and 0.08 wt% butylated hydroxytoluene; an inside wall that surrounds the layers comprising ethylcellulose, hydroxypropylcellulose and polyvinylpyrrolidone; an outside wall that surrounds the inside wall comprising cellulose acetate and a surfactant; and an exit in the walls for releasing the morphine from the dosage  
15 form.

22. A method of administering a unit dose of opioid analgesic to a patient in need of opioid analgesia, where in the method comprises administering zero to 15 percent of the dose for zero hours to four hours, then  
20 15 percent to 55 percent of the dose for four hours to eight hours, 55 percent to 75 percent of the dose for eight to twelve hours, and 75 percent to 100 percent of the unit dose for twelve hours to twenty-four hours.

23. A method of administering a dose of an opioid analgesic to a patient in need of an opioid analgesic, wherein the method comprises administering to the patient a dosage form tablet comprising 1 mg to 1000 mg  
25 of an opioid analgesic that is administered in a dose of 2 mg to 8 mg from zero hours to eighteen hours and 2 mg to zero mg from eighteen hours to twenty-four hours for administering the opioid analgesic to the patient.

30           24. A process for increasing the rate of drug released from a dosage form, wherein the process comprises: enveloping a dose of drug with



5 a wall comprising a passage-former that, in the presence of fluid, leaves the wall and lets more fluid into the dosage form for increasing the release of drug over a sustained-release period up to twenty-four hours from the dosage form; and enveloping the wall with a different wall that provides support to the dosage form.

10 25. A process for maintaining an extended-linear, non-declining release drug profile from a dosage form comprising a core of drug, wherein the process comprises: coating a core comprising a drug with a composition comprising a passage former that, leaves the composition in the presence of fluid and correspondingly make available an increase in passages that increase fluid inflow into the dosage form over time; and, coating the coated composition with a coat that provides fluid to the coated composition, whereby through the coat and the coated composition, the dosage form  
15 maintains the delivery over time.

20 26. A dosage form for delivering a drug at a sustained-release rate to a gastrointestinal-lipid-fluid environment of use, wherein the dosage form comprises: a composition comprising a dose of drug; a coat that envelopes the composition comprising the drug, which coat comprises a passage-former that leaves the coat in the presence of fluid; and a wall that surrounds the coat and prevents lipid in the gastrointestinal tract from entering the dosage form.

25 27. The dosage form according to claim 26, wherein the coat lets an increasing volume of fluid into the coated composition comprising the drug.

1/4




FIG. 1




FIG. 2

FIG. 4

FIG. 4

3/4




FIG. 5




FIG. 6




FIG. 7




FIG. 8

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/04192

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/24 A61K9/36 B32B23/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K B32B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI Section Ch, Week 9724 Derwent Publications Ltd., London, GB; Class A11, AN 97-267704 XP002900470 &amp; JP 09 095440 A (MORISHITA ROUSSEL KK) , 8 April 1997 see abstract</p> <p>---</p>	1
X	<p>EP 0 649 657 A (EURO-CELTIQUE S.A.) 26 April 1995 see page 3; claims</p> <p>---</p>	5,6
X	<p>EP 0 068 838 A (THE UPJOHN COMPANY) 5 January 1983 see examples</p> <p>---</p>	10,11
	<p>---</p> <p>-/--</p>	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*Z\* document member of the same patent family

Date of the actual completion of the international search

25 May 1999

Date of mailing of the international search report

22 JULY 1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

MOSSER

## INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 99/04192

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 85 03436 A (A/S ALFRED BENZON) 15 August 1985 see claims 1-15 ---	15-17
Y	US 4 705 039 A (SAKAGUCHI ET AL.) 10 November 1987 see the whole document -----	15-17

## INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 99/04192

**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark: Although claims 22 and 23 concern a method for treatment of the human/animal body by therapy (see PCT Rule 39.1(iv)), the search was carried out and based on the alleged effects.**

2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/04192

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 649657	A	26-04-1995	AU 7414694 A	06-04-1995
			CA 2132568 A	23-03-1995
			CN 1108934 A	27-09-1995
			IL 111044 A	06-12-1998
			JP 7330628 A	19-12-1995
			NO 943511 A	23-03-1995
			US 5763452 A	09-06-1998
			US 5908848 A	01-06-1999
			ZA 9407305 A	10-05-1995
EP 68838	A	05-01-1983	JP 58004720 A	11-01-1983
			US 4489080 A	18-12-1984
WO 8503436	A	15-08-1985	AU 571312 B	14-04-1988
			AU 3935985 A	27-08-1985
			CA 1247009 A	20-12-1988
			DE 3586600 A	15-10-1992
			DK 462685 A,B,	09-10-1985
			EP 0153105 A	28-08-1985
			HK 1000201 A	06-02-1998
			IE 59287 B	09-02-1994
			JP 7059499 B	28-06-1995
			JP 61501150 T	12-06-1986
			US 4716041 A	29-12-1987
			AU 570540 B	17-03-1988
			AU 3935885 A	27-08-1985
			CA 1248023 A	03-01-1989
			DE 3587274 A	27-05-1993
			DK 462585 A,B,	09-10-1985
			WO 8503437 A	15-08-1985
			EP 0153104 A	28-08-1985
			FI 853934 A,B	09-10-1985
			HK 1001554 A	26-06-1998
			IE 59797 B	06-04-1994
			JP 7059500 B	28-06-1995
			JP 61501151 T	12-06-1986
			NO 173316 C	01-12-1993
			US 4713248 A	15-12-1987
US 4705039	A	10-11-1987	NONE	